EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Lysyl oxidase‐like 2 promotes stemness and enhances antitumor effects of gefitinib in head and neck cancer via IFIT1 and IFIT3

Yi-Jie Lu iD, Yi-Ting Deng, Hui-Hsin Ko, Hsin-Hui Peng, Hsiang-Chieh Lee iD, Mark Yen-Ping Kuo iD, Shih-Jung Cheng iD

Cancer Science · 2023

DOI: 10.1111/cas.15912 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Yi-Jie Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Oral Biology, College of Medicine, National Taiwan University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Mouth Neoplasms, Head and Neck Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lysyl oxidase‐like 2 (LOXL2) is a matrix‐remodeling enzyme that has recently been identified as an important regulator of tumor progression and metastasis. This study discovered that LOXL2 expression in oral squamous cell carcinoma (OSCC) tissues was significantly associated with tumor clinical stage, lymph node metastasis and patients' overall survival time. LOXL2‐overexpressing human buccal SCC TW2.6 (TW2.6/LOXL2) and hypopharyngeal SCC FaDu (FaDu/LOXL2) cells exhibited enhanced migration, invasion, epithelial–mesenchymal transition (EMT), and cancer stem cell (CSC) phenotypes, independently of its enzymatic activity. Moreover, TW2.6/LOXL2 significantly increased tumor‐initiating frequency in SCID mice. We further demonstrated that LOXL2 increased the levels of interferon‐induced protein with tetratricopeptide repeats 1 (IFIT1) and IFIT3 in TW2.6/LOXL2 and FaDu/LOXL2 cells. We also identified IFIT1 and IFIT3 as key downstream components of LOXL2 action in migration, invasion, EMT, and CSC phenotypes in TW2.6 and FaDu cells. Furthermore, a significant positive correlation between LOXL2 expression and IFIT1 and IFIT3 overexpression in human OSCC tissues was observed. In addition, TW2.6/LOXL2 and FaDu/LOXL2 cells were 3.3‐ to 3.6‐fold more susceptible to the epidermal growth factor receptor (EGFR) inhibitor gefitinib than were their respective control cells. The antitumor effect of gefitinib on orthotopic TW2.6/LOXL2 xenograft tumor was fourfold higher than that on controls. Our results indicate that LOXL2 expression is a strong prognostic factor for OSCC and may be used as a marker to identify patients most likely to respond to EGFR‐targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellMouth NeoplasmsHead and Neck NeoplasmsAnimalsMiceHumansGefitinibProtein-Lysine 6-OxidaseMice, SCIDSquamous Cell Carcinoma of Head and NeckRNA-Binding ProteinsErbB ReceptorsGene Expression Regulation, NeoplasticEpithelial-Mesenchymal TransitionCell Line, TumorIntracellular Signaling Peptides and ProteinsAdaptor Proteins, Signal Transducing

Stichwörter der Autor:innen

cancer stem cellsgefitinibinterferon-induced protein with tetratricopeptide repeats 1interferon-induced protein with tetratricopeptide repeats 3lysyl oxidase-like 2

Substanzen

GefitinibProtein-Lysine 6-OxidaseRNA-Binding ProteinsErbB ReceptorsIntracellular Signaling Peptides and ProteinsIFIT3 protein, humanIFIT1 protein, humanAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Graduate Institute of Oral Biology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Dentistry, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan.
  • Graduate Institute of Photonics and Optoelectronics, National Taiwan University, Taipei, Taiwan.
  • Department of Dentistry, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Dentistry, National Taiwan University Hospital, Taipei, Taiwan.

ORCID-Profile: Yi-Jie Lu, Hsiang-Chieh Lee, Mark Yen-Ping Kuo, Shih-Jung Cheng

Förderung

  • Ministry of Science and Technology, Taiwan

Zitieren

APA

Lu, Y. J., Deng, Y. T., Ko, H. H., Peng, H. H., Lee, H. C., Kuo, M. Y., & Cheng, S. J. (2023). Lysyl oxidase‐like 2 promotes stemness and enhances antitumor effects of gefitinib in head and neck cancer via IFIT1 and IFIT3. Cancer Science. https://doi.org/10.1111/cas.15912

Vancouver

Lu YJ, Deng YT, Ko HH, Peng HH, Lee HC, Kuo MY, et al. Lysyl oxidase‐like 2 promotes stemness and enhances antitumor effects of gefitinib in head and neck cancer via IFIT1 and IFIT3. Cancer Science. 2023. doi:10.1111/cas.15912

BibTeX
@article{Lu2023,
  author = {Lu, Yi-Jie and Deng, Yi-Ting and Ko, Hui-Hsin and Peng, Hsin-Hui and Lee, Hsiang-Chieh and Kuo, Mark Yen-Ping and Cheng, Shih-Jung},
  title = {Lysyl oxidase‐like 2 promotes stemness and enhances antitumor effects of gefitinib in head and neck cancer via IFIT1 and IFIT3},
  journal = {Cancer Science},
  year = {2023},
  doi = {10.1111/cas.15912}
}
Kostenlos starten →